Evidence map›Paper›PMID 40796998›Full record

ArticleBiotechnology letters2025

Identification and characterisation of subtype-specific anti-N-CoR OSGEP protease in acute myeloid leukaemia (AML-M5) cell lineage.

S Annie Jeyachristy, Eshan Rosly Nazem, Ramesh Thevendran, Ahsas Goyal, Kavita Goyal, Solayappan Maheswaran, Atreyi Pramanik, Gaurav Gupta, Neeraj Kumar Fuloria, Shivkanya Fuloria and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

S Annie JeyachristyFaculty of Medicine, Royal College of Medicine Perak, Universiti Kuala Lumpur (UniKL RCMP), 30450, Ipoh , Perak, Malaysia. sam.annie@unikl.edu.my.ORCID http://orcid.org/0009-0009-7746-9417
Eshan Rosly NazemDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Bedong, Malaysia.
Ramesh ThevendranDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Bedong, Malaysia.
Ahsas GoyalInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, 281406, India.
Kavita GoyalDepartment of Biotechnology, Graphic Era (Deemed to Be University), Clement Town, Dehradun, 248002, India.
Solayappan MaheswaranDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Bedong, Malaysia.
Atreyi PramanikSchool of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Gaurav GuptaCentre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Neeraj Kumar FuloriaFaculty of Pharmacy, AIMST University, 08100, Semeling, Kedah, Malaysia.
Shivkanya FuloriaFaculty of Pharmacy, AIMST University, 08100, Semeling, Kedah, Malaysia.
Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehradun, Uttarakhand, 248007, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a neoplastic disorder of the myeloid stem cell and is most commonly diagnosed in children and young adults. N-CoR is an essential protein that regulates transcriptional repression in normal myeloid cell development Mutations or loss of function in the N-CoR gene result in the abnormal expression of critical genes involved in cell proliferation, contributing to leukemogenic transformation and the development of malignancy in acute myeloid leukemia subtype M5 (AML-M5). This study was aimed to elucidate the mechanism of N-CoR degradation by O-sialo-glycoprotein endopeptidase (OSGEP), a protease that is active in AML-M5 cells only. The AML-M5-specific proteases were isolated using HPLC size exclusion chromatography and anti-N-CoR OSGEP antibodies. In vitro experiments were performed to test the degradation of recombinant N-CoR protein by OSGEP protease. The protease's identity and composition were analyzed via mass spectrometry. Study involved transfection studies using various cell lines to evaluate the subtype-specific activity of OSGEP based on N-CoR expression levels. Study findings revealed OSGEP protease to cleave N-CoR in AML-M5 cells. Mass spectrometry confirmed the identity and composition of a purified, functionally active form of the OSGEP protease. The transfection studies proved that N-CoR was the only protein of the two that OSGEP protease acted on selectively in AML-M5 cells thus proving its specificity in the subtype of cells. Findings of present study suggests that OSGEP protease-mediated N-CoR degradation is an important factor in the development of AML-M5. Current study highlights N-CoR degradation by OSGEP as a key molecular event in AML-M5 and proposes the N-CoR protease as a potential diagnostic and therapeutic biomarker for this leukemia subtype.

Indexed as

EndopeptidasesLeukemia, Myeloid, AcuteCell Line, TumorHumansEndopeptidasesAcute myeloid leukaemiaAnti-N-CoR OSGEPHPLCLeukaemia biomarkersMyeloid cellsN-CoRProtein expression

Identifiers

PMID40796998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.